About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT01391637

Long-Term Follow-Up Study of Human Stem Cells Transplanted in Subjects With Connatal Pelizaeus-Merzbacher Disease (PMD)

The purpose of this study is to determine the long term safety and preliminary effect of HuCNS-SC cells transplanted in subjects with Connatal Pelizaeus-Merzbacher Disease (PMD).

Lead sponsor: StemCells, Inc.•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

StemCells, Inc.

Only subjects who underwent HuCNS-SC transplantation under Protocol CL-N01-PMD will be enrolled in this long term follow-up study. Subjects will return to the site six months and one year after completion of the Phase I study and then annually for a total study duration of four years. Phone calls will also be made by the Investigator to the subject's parent/legal guardian bi-annually to conduct a phone visit through the four-year duration of the study.

Age

All ages

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Subjects who received HuCNS-SC cells under Protocol CL-N01-PMD

Exclusion Criteria

•Subjects who received off-protocol immunosuppressive medications.
•Subjects who are concurrently enrolled in another investigational study.

Related studies

Longitudinal Study of Neurodegenerative Disorders

NCT03333200 · MLD, Krabbe Disease, and more

Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease

NCT05659901 · Pelizaeus-Merzbacher Disease

The Myelin Disorders Biorepository Project

NCT03047369 · Leukodystrophy, White Matter Disease, and more

RECRUITINGPhase 1

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

NCT02254863 · Adrenoleukodystrophy, Batten Disease, and more

RECRUITINGPhase 4

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

NCT06704594 · Premenstrual Dysphoric Disorder (PMDD)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 13, 2016Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment4

Start dateJun 2011

Last updatedMay 13, 2016

Condition

Pelizaeus-Merzbacher Disease PMD

Locations shown

UCSF Medical Center

San Francisco, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 13, 2016Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions